Patents by Inventor Yoichi Kita
Yoichi Kita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11479552Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.Type: GrantFiled: July 15, 2021Date of Patent: October 25, 2022Assignee: Eisai R&D Management Co., Ltd.Inventors: Yu Yoshida, Yoichi Kita, Makoto Kotake, Keiichi Sorimachi, Toshiyuki Ohfusa, Takafumi Motoki, Taro Asaba
-
Publication number: 20220017517Abstract: Provided are compounds represented by the following formulas (I), (II), (III) and (IV) having orexin type 2 receptor-activating activity, or their pharmaceutically acceptable salts.Type: ApplicationFiled: July 15, 2021Publication date: January 20, 2022Applicant: Eisai R&D Management Co., Ltd.Inventors: Yu YOSHIDA, Yoichi KITA, Makoto KOTAKE, Keiichi SORIMACHI, Toshiyuki OHFUSA, Takafumi MOTOKI, Taro ASABA
-
Patent number: 9738656Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:Type: GrantFiled: November 9, 2016Date of Patent: August 22, 2017Assignee: Eisai R&D Management Co., Ltd.Inventors: Toshiki Kurokawa, Yu Yoshida, Kogyoku Shin, Yoshihisa Kobayashi, Hironori Fukumoto, Kunitoshi Takeda, Yoshiaki Ohashi, Makoto Kotake, Tomoyuki Shibuguchi, Toru Watanabe, Yoichi Kita, Shinsuke Hirota, Takashi Fukuyama, Yasuaki Kamada
-
Publication number: 20170137436Abstract: Compounds represented by formulae (I) to (XXII) or pharmaceutically acceptable salts thereof:Type: ApplicationFiled: November 9, 2016Publication date: May 18, 2017Inventors: Toshiki Kurokawa, Yu Yoshida, Kogyoku Shin, Yoshihisa Kobayashi, Hironori Fukumoto, Kunitoshi Takeda, Yoshiaki Ohashi, Makoto Kotake, Tomoyuki Shibuguchi, Toru Watanabe, Yoichi Kita, Shinsuke Hirota, Takashi Fukuyama, Yasuaki Kamada
-
Patent number: 9018260Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.Type: GrantFiled: June 17, 2013Date of Patent: April 28, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
-
Patent number: 8946211Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: March 14, 2013Date of Patent: February 3, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Yoichi Kita, Kunitoshi Takeda, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Patent number: 8946210Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: December 21, 2011Date of Patent: February 3, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Yoichi Kita, Kunitoshi Takeda, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Publication number: 20140371319Abstract: Novel indansulfamide derivatives or a pharmaceutically acceptable salt thereof such as N-[(1S)-2,2,5,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, N-[(1S)-2,2,4,7-tetrafluoro-2,3-dihydro-1H-inden-1-yl]sulfamide, (+)-N-(2,2,4,6,7-pentafluoro-2,3-dihydro-1H-inden-1-yl)sulfamide, have an action of improving Seizure Severity Index (Score) in mice kindling model. Thus the compounds or the salt thereof are expected as a drug for treating epilepsy.Type: ApplicationFiled: June 17, 2013Publication date: December 18, 2014Applicant: Eisai R&D Management Co., Ltd.Inventors: Yuji Kazuta, Toru Watanabe, Keiichi Sorimachi, Minako Saito, Yoichi Kita, Toshiaki Tanaka, Hiroyuki Higashiyama, Takahisa Hanada, Tetsuyuki Teramoto, Takashi Kosasa, Yukio Ishikawa
-
Patent number: 8822455Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C1-6alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C1-6alkyl, C2-3alkenyl, C2-3alkynyl, C1-6alkoxy, C3-6cycloalkoxy and pyrazine, where C1-6alkyl and C1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: January 5, 2012Date of Patent: September 2, 2014Assignee: Eisai R&D Management Co., Ltd.Inventors: Paschalis Dimopoulos, Adrian Hall, Yoichi Kita, Andrew Madin, Nicola Louise Shuker
-
Publication number: 20140011802Abstract: The present invention relates to a fused aminodihydrothiazine derivative of formula (I): wherein R is hydrogen or C1-6 alkyl, optionally substituted by one to five halogen atoms; n is 0, 1, 2 or 3; Ar is phenyl or a 5- or 6-membered heteroaromatic group containing 1, 2 or 3 N atoms, which Ar is optionally substituted by one to three substituents selected from hal, hydroxyl, —CN, C1-6alkyl, C2-3alkenyl, C2-3alkynyl,C-6alkoxy, C3-6cycloalkoxy and pyrazine, where C1-6alkyl and C1-6alkoxy are optionally substituted by one to three halogen atoms; and pharmaceutically acceptable salts thereof; which compound has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease 1 caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: January 5, 2012Publication date: January 9, 2014Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Paschalis Dimopoulos, Adrian Hall, Yoichi Kita, Andrew Madin, Nicola Louise Shuker
-
Patent number: 8198269Abstract: A compound represented by the general formula: wherein Ring A is a C6-14 aryl group or the like, L is —NRLCO— or the like (wherein RL is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a C1-3 alkylene group or the like, Z is an oxygen atom or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: September 28, 2009Date of Patent: June 12, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Takafumi Motoki, Kunitoshi Takeda, Yoichi Kita, Mamoru Takaishi, Yuichi Suzuki, Tasuku Ishida
-
Publication number: 20120094984Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Patent number: 8158620Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: January 16, 2009Date of Patent: April 17, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Publication number: 20110207723Abstract: A compound represented by the general formula (I): a pharmaceutically acceptable salt thereof, or a solvate of the compound or salt has an A? production inhibitory activity or BACE 1 inhibitory activity, and is thus useful as an agent for treating neurodegenerative diseases caused by A? as typified by Alzheimer's disease. In the formula, ring A represents a C6-14 aryl group or the like; L represents —NR1CO— (wherein RL represents a hydrogen atom or the like) or the like; ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a C1-3 alkylene group or the like; Z represents an oxygen atom or the like; R1 and R2 each independently represents a hydrogen atom or the like; and R3, R4, R5 and R6 each independently represents a hydrogen atom, a halogen atom or the like.Type: ApplicationFiled: September 28, 2009Publication date: August 25, 2011Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Takafumi Motoki, Kunitoshi Takeda, Yoichi Kita, Mamoru Takaishi, Yuichi Suzuki, Tasuku Ishida
-
Publication number: 20100317850Abstract: Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of A? or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for A?-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C6-14 aryl group or the like; L represents —NReCO— [wherein Re represents a hydrogen atom or the like] or the like; the ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a single bond or the like; Z represents a C1-3 alkylene group or the like; R1 and R2 independently represent a hydrogen atom or the like; and R3, R4, R5 and R6 independently represent a hydrogen atom, a halogen atom or the like.Type: ApplicationFiled: January 16, 2009Publication date: December 16, 2010Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Publication number: 20100093999Abstract: A compound represented by the general formula: wherein Ring A is a C6-14 aryl group or the like, L is —NRLCO— or the like (wherein RL is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a C1-3 alkylene group or the like, Z is an oxygen atom or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, or a pharmaceutically acceptable salt thereof, or a solvate thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: September 28, 2009Publication date: April 15, 2010Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Takafumi Motoki, Kunitoshi Takeda, Yoichi Kita, Mamoru Takaishi, Yuichi Suzuki, Tasuku Ishida
-
Publication number: 20090209755Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: January 16, 2009Publication date: August 20, 2009Inventors: Yuichi SUZUKI, Takafumi MOTOKI, Toshihiko KANEKO, Mamoru TAKAISHI, Tasuku ISHIDA, Yoichi KITA, Kunitoshi TAKEDA, Noboru YAMAMOTO, Afzal KHAN, Paschalis DIMOPOULOS
-
Patent number: 5886895Abstract: For calculating optimum operation parameters of a BTG plant including a plurality of boilers having a linear input/output characteristic between an incoming fuel and steam output and a plurality of turbines having a non-convex input/output characteristic between the incoming steam which is an output of the boiler and power output, a dynamic programming process is performed twice and a linear programming process is performed once with respect to the steam and power to find, as an optimum solution, the power output of the turbines. Finally, an optimum solution is found in which a total fuel cost is minimized.Type: GrantFiled: July 1, 1996Date of Patent: March 23, 1999Assignee: Kabushiki Kaisha ToshibaInventors: Yoichi Kita, Tohru Kamibayashi